BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Koizumi A, Kaji K, Nishimura N, Asada S, Matsuda T, Tanaka M, Yorioka N, Tsuji Y, Kitagawa K, Sato S, Namisaki T, Akahane T, Yoshiji H. Effects of elafibranor on liver fibrosis and gut barrier function in a mouse model of alcohol-associated liver disease. World J Gastroenterol 2024; 30(28): 3428-3446 [PMID: 39091710 DOI: 10.3748/wjg.v30.i28.3428]
URL: https://www.wjgnet.com/2150-5330/full/v30/i28/3428.htm
Number Citing Articles
1
Siva Sundara Kumar Durairajan, Abhay Kumar Singh, Ashok Iyaswamy. Peroxisome proliferator-activated receptor agonists: A new hope towards the management of alcoholic liver diseaseWorld Journal of Gastroenterology 2024; 30(35): 3965-3971 doi: 10.3748/wjg.v30.i35.3965
2
Fei-Qiong Gao, Jia-Qi Zhu, Xu-Dong Feng. Novel intervention for alcohol-associated liver diseaseWorld Journal of Gastroenterology 2024; 30(39): 4308-4312 doi: 10.3748/wjg.v30.i39.4308
3
Xin-Yang Zhang, Qin-Jun-Jie Chen, Feng Zhu, Min Li, Dan Shang. Dual peroxisome proliferator-activated receptor α/δ agonists: Hope for the treatment of alcohol-associated liver disease?World Journal of Gastroenterology 2024; 30(37): 4163-4167 doi: 10.3748/wjg.v30.i37.4163
4
Hong Wei, Li-Xuan Sang, Bing Chang. Elafibranor: A promising treatment for alcohol-associated liver disease?World Journal of Gastroenterology 2024; 30(39): 4313-4317 doi: 10.3748/wjg.v30.i39.4313
5
Youtian Zhang, Long Ren, Yinting Tian, Xiaohu Guo, Fengxian Wei, Yawu Zhang. Signaling pathways that activate hepatic stellate cells during liver fibrosisFrontiers in Medicine 2024; 11 doi: 10.3389/fmed.2024.1454980
6
Manman Hou, Pin Song, Yue Chen, Xiaoran Yang, Pengnan Chen, Aizhi Cao, Yingdong Ni. Bile acids supplementation improves colonic mucosal barrier via alteration of bile acids metabolism and gut microbiota composition in goats with subacute ruminal acidosis (SARA)Ecotoxicology and Environmental Safety 2024; 287: 117313 doi: 10.1016/j.ecoenv.2024.117313
7
Hang Zhang, Xuan Dong, Lei Zhu, Fu-Shan Tang. Elafibranor: A promising treatment for alcoholic liver disease, metabolic-associated fatty liver disease, and cholestatic liver diseaseWorld Journal of Gastroenterology 2024; 30(40): 4393-4398 doi: 10.3748/wjg.v30.i40.4393
8
Yu-Qi Sun, Yang Wu, Meng-Ran Li, Yu-Yao Wei, Mei Guo, Zi-Li Zhang. Elafibranor alleviates alcohol-related liver fibrosis by restoring intestinal barrier functionWorld Journal of Gastroenterology 2024; 30(43): 4660-4668 doi: 10.3748/wjg.v30.i43.4660